Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: An 11-year follow-up

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 241, Issue 12, 2003, Pages 996-999

  Aisenbrey, Sabine ^a   Lüke, Christoph ^a   Ayertey, Helen D ^a   Grisanti, Salvatore ^b   Perniok, Andreas ^a   Brunner, Richard ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE;

ADULT; ALOPECIA; ARTICLE; AUTOIMMUNITY; CANCER RECURRENCE; CASE REPORT; CATARACT; CATARACT EXTRACTION; COMPUTER ASSISTED PERIMETRY; DEPIGMENTATION; DISEASE ASSOCIATION; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HAIR GROWTH; HLA TYPING; HUMAN; HYPERSENSITIVITY; HYPOTHESIS; IMMUNITY; LYMPH NODE METASTASIS; MELANOCYTE; MELANOMA; MENINGOENCEPHALITIS; OPTIC DISK; PERIMETRY; PIGMENTATION; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA PIGMENT EPITHELIOPATHY; SKIN SURGERY; SKIN TUMOR; SYMPTOM; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; VITILIGO; VOGT KOYANAGI SYNDROME;

FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; PERIMETRY; SKIN NEOPLASMS; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY;

EID: 0348230347     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-003-0787-5     Document Type: Article

References (29)

1. Alaez C, del Pilar Mora M, Arellanes L, et al (1999) Strong association of HLA class II sequences in Mexicans with Vogt-Koyanagi-Harada disease. Hum Immunol 60:875-882
2. Boyd SR, Young S, Lightman S (2001) Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 46:209-233
3. Chang MA, Fournier G, Koh HK, Sober AJ, Nakagawa H, Fitzpatrick TB, Albert DM (1986) Ocular abnormalities associated with cutaneous melanoma and vitiligoloke leukoderma. Graefes Arch Clin Exp Ophthalmol 224:529-535
4. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC (2001) A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol 22:130-136
5. Kim MH, Seong MC, Kwak NH, et al (2000) Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol 129:173-177
6. Kuo IC, Rechdouni A, Rao NA, et al (2000) Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology 107:1721-1728
7. Lertsumitkul S, Whitcup SM, Nussen-blatt RB, Chan CC (1999) Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol 113:1039-1045
8. Lubin JR, Ni C, Albert DM (1982) Clinicopathological study of the Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin 22:141-156
9. Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M (2000) Thick cutaneous melanoma: a reappraisal of prognostoc factors. Melanoma Res 10:153-164
10. Matsuda H (1970) Electron microscopic studies on Vogt-Koyanagi-Harada syndrome and sympathetic ophthalmia with special reference to the melanocyte. Nippon Ganka Gakkai Zasshi 74:1107-1112
11. Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39:265-292
12. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689-696
13. Nussenblatt RB, Palestine AG, Whitcup SM, Craven L (1995) Vogt-Koyanagi-Harada syndrome. In: Uveitis: fundamental and clinical practice, 2nd edn. Mosby, St Louis
14. Ohno S (1981) Immunological aspects of Behcet's and Vogt-Koyanagi-Harada diseases. Trans Ophthalmol Soc UK 101:335-341
15. Ohno S, Minakawa R, Matsuda H (1988) Clinical studies of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 32:334-343
16. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742-747
17. Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274-278
18. Rao NA (1997) Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye 11:213-216
19. Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET (1999) Vogt-Koyanagi-Harada syndrome after cutaneous injury. Ophthalmology 106:635-638
20. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arrellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol 131:647-652
21. Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, Rao NA (2001) Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:599-606
22. Rubsamen PE, Gass JD (1991) Vogt-Koyanagi-Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol 109:682-687
23. Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R (1997) Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 80:1426-1431
24. Sakamoto T, Murata T, Inomata H (1991) Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol 109:1270-1274
25. Sober AJ, Haynes HA (1978) Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 114:439-441
26. Sonoda S, Nakao K, Ohba N (1999) Extensive chorioretinal atrophy in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 43:113-119
27. Sugiura S (1978) Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 22:9-35
28. Zetterstein E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SPL, Kashani-Sabet M (2002) Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 95:1049-1056
29. Zhao M, Jiang Y, Abrahams IW (1991) Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Arch Ophthalmol 109:368-370